Drug Profile
Apomorphine subcutaneous - Neuroderm
Alternative Names: ND-0701Latest Information Update: 20 Aug 2020
Price :
$50
*
At a glance
- Originator NeuroDerm
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 25 Jul 2020 Discontinued - Clinical-Phase-Unknown for Parkinson's disease (In volunteers) in European Union (SC) (Mitsubishi Tanabe Pharma Corporation's pipeline, August 2020)
- 25 Jul 2020 Discontinued - Phase-I for Parkinson's disease (Treatment-experienced) in Israel (SC) (Mitsubishi Tanabe Pharma Corporation's pipeline, August 2020)
- 06 Aug 2018 Chemical structure information added